Veloxis Pharmaceuticals Competitors and Similar CompaniesClear all
Veloxis Pharmaceuticals's competitors and similar companies include OptiNose, Oncologie, CTI BioPharma and Sea4Us.
 Veloxis Pharmaceuticals Veloxis Pharmaceuticals is a biopharmaceutical company, which identifies, develops, and commercializes products that are used in transplantation and adjacent therapies. |  CTI BioPharma CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. |  Sea4Us Sea4Us is a biopharmaceutical company focused on the discovery and development of pharmaceutical drugs based on marine compounds. | |||
Founding Date | Founding Date 2002 | Founding Date 2000 | Founding Date 2018 | Founding Date 1992 | Founding Date 2013 |
Type | Type Public | Type Public | Type Private | Type Public | Type Private |
Tags | |||||
Locations | Locations København, DK HQ Cary, US Cary, US | Locations Morrisville, US HQ Oslo, NO Swindon, GB | Locations Waltham, US HQ Shanghai, CN Boston, US | Locations Seattle, US HQ Köln, DE | Locations Budens, PT HQ |
Employees | Employees 54 | Employees 2048% decrease | Employees 8 | Employees 2546% decrease | Employees 24 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 118.1 m | Valuation ($) N/A | Valuation ($) 1.2 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) kr39.5m (FY, 2018) | Revenue (est.) $71m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $53.9m (FY, 2022) | Revenue (est.) N/A |
Cost of goods | Cost of goods kr7.9m (FY, 2018) | Cost of goods $8.6m (FY, 2023) | Cost of goods N/A | Cost of goods $3.5m (FY, 2022) | Cost of goods N/A |
Gross profit | Gross profit kr31.6m (FY, 2018) | Gross profit N/A | Gross profit N/A | Gross profit $50.4m (FY, 2022) | Gross profit N/A |
Net income | Net income (kr5.3m) (FY, 2018) | Net income ($35.5m) (FY, 2023) | Net income N/A | Net income ($93m) (FY, 2022) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised $ 60m | Total funding raised $ 120.5m | Total funding raised $ 96.5m | Total funding raised $ 105m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
OptiNose
HQ
Morrisville, US
Employees
204↓ 8% decrease
OptiNose develops nasal drug delivery technologies and combination drug-device therapies.
View companyCTI BioPharma
HQ
Seattle, US
Employees
25↓ 46% decrease
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers.
View companySea4Us
HQ
Budens, PT
Employees
24
Sea4Us is a biopharmaceutical company focused on the discovery and development of pharmaceutical drugs based on marine compounds.
View company